{
    "nctId": "NCT06000917",
    "briefTitle": "A Study of Neoadjuvant TCHpy\uff08Pyrotinib \uff0cTrastuzumab\uff0cCarboplatin and Paclitaxel\uff09for ER+/HER2+ Breast Cancer",
    "officialTitle": "A Multicenter, Single-arm, Prospective Study of Neoadjuvant Pyrotinib Combined With Trastuzumab\uff0cCarboplatin and Paclitaxel for ER+/HER2+ Early or Locally Advanced Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Neoadjuvant",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 62,
    "primaryOutcomeMeasure": "total Pathological Complete Response(tPCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly treated female patients aged \u226518 years and \u226475 years;\n* ECOG score 0\\~1;\n* Pathologically diagnosed as HER2-positive breast cancer patients with early or locally advanced tumor stage, primary tumor diameter T\u22652cm or lymph node positive;\n* Hormone receptor status (ER and PgR) is known, where ER\u226510%\n* Normal function of major organs:\n\n  1. The standard of blood routine examination should meet: ANC \u22651.5\u00d7109/L; PLT\u226590\u00d7109/L; Hb \u226590g/L\n  2. Biochemical examination should meet the following standards: TBIL\u2264 the upper limit of normal value(ULN); ALT and AST\u22641.5 times the upper limit of normal (ULN); Alkaline phosphatase \u22642.5 times the upper limit of normal (ULN); BUN and Cr\u22641.5\u00d7ULN and creatinine clearance \u226550 mL/min (CockcroftGault formula);\n  3. Cardiac color ultrasound and echocardiography: left ventricular ejection fraction(LVEF\u226555%)\n  4. Fridericia calibrated QT interval (QTcF) for 18-lead ECG \\<470 ms;\n* For female patients who are not menopausal or have not been surgically sterilized: consent to abstinence or use of an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment;\n* Volunteer to join the study and sign the informed consent.\n\nExclusion Criteria:\n\n* Stage IV (metastatic) breast cancer;\n* Inflammatory breast cancer;\n* Previous antitumor therapy or radiation therapy for any malignancies, excluding cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma;\n* Also receiving antitumor therapy in other clinical trials, including endocrine therapy, bisphosphonate therapy, or immunotherapy;\n* Had a major surgery not related to breast cancer in the 4 weeks prior to enrollment, or had not fully recovered from such surgery;\n* Serious heart disease or discomfort, including but not limited to the following:\n\n  * History of heart failure or systolic dysfunction (LVEF \\< 50%)\n  * High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate \\>100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia), or higher-grade atrioventricular block (i.e. Mobitz II second- degree atrioventricular block or third-degree atrioventricular block\n* Inability to swallow, intestinal obstruction, or other factors affecting the use and absorption of the drug;\n* Known allergic history of the drug components of this protocol; A history of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;\n* Women who are pregnant or nursing, women who are fertile and have a positive baseline pregnancy test, or women of childbearing age who are unwilling to use effective contraception throughout the trial period and within 7 months after the last study medication;\n* Have a serious concomitant condition or other comorbid condition that interferes with planned treatment, or any other condition in which the investigator deems the patient unsuitable for participation in the study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}